Diadema Partners »

Pyxis Oncology shares owned by Diadema Partners

Quarter-by-quarter ownership of Pyxis Oncology (PYXS) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Pyxis Oncology

Tip: Access up to 7 years of quarterly data

All positions including Pyxis Oncology held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Pyxis Oncology by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $333k 150k 2.22

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Pyxis Oncology

Pfizer
Laurion Capital Management
Tang Capital Management
Vanguard Group
Perceptive Advisors
Palo Alto Investors
Millennium Management
Stempoint Capital
BlackRock
Renaissance Technologies
Geode Capital Management
683 Capital Management
Driehaus Capital Management
UBS Group
Citadel Advisors

View all funds holding Pyxis Oncology